NCT01587898COMPLETEDanonymous

A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis

Sponsor

Source record

GlaxoSmithKline

Phase

Source record

Phase IIa

Modality

AI-normalized

small molecule

Target

AI-normalized

Anemia associated with Chronic Kidney Disease

Indication / condition

AI-normalized

Anaemia

Intervention

Source record

GSK1278863, Placebo

Source & freshness

Source record

NCT ID

NCT01587898

Original source

ClinicalTrials.gov

Source last updated

Nov 09, 2017

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT01587898

Title

A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis

Sponsor

GlaxoSmithKline

Status

COMPLETED

Phase

Phase IIa

Condition raw

Anaemia

Condition normalized

Anaemia

Modality raw

Anaemia

Modality normalized

small molecule

Target raw

Anemia associated with Chronic Kidney Disease

Target normalized

Anemia associated with Chronic Kidney Disease

Interventions

GSK1278863, Placebo

Public preview

Source record

The study evaluated GSK1278863, a prolyl hydroxylase inhibitor, for treating anemia in patients with chronic kidney disease not on dialysis. Conducted by GlaxoSmithKline, the trial involved 72 participants and aimed to assess safety, efficacy, and pharmacokinetics over four weeks.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01587898

Status

COMPLETED

Phase

Phase IIa

Sponsor

GlaxoSmithKline

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedNov 09, 2017

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01587898

Indication

Anaemia

Modality

small molecule

Target

Anemia associated with Chronic Kidney Disease

Intervention

GSK1278863, Placebo

Source record